Inflammatory Bowel Disease (IBD)

TARGET-IBD is currently enrolling


The need for the real world, longitudinal data is critical for inflammatory bowel disease, where a robust pipeline of new chemical entities and bio-similar entrants will have a profound effect on patient management. 

Initial Goals include:

  • Expand enrollment of the TARGET-IBD cohort with rapid acquisition of detailed clinical data from academic and community practice settings
  • Explore the safety and effectiveness of the entire spectrum of current and future therapies (including the occurrence of switching to bio-similars) that are utilized in usual clinical practice across diverse populations

Launched: August, 2017

Targeted number of patients: 15,000

TARGET-IBD Steering Committee

Bruce Sands, MD (co-Chair)
Dr. Burrill B. Crohn Professor of Medicine at Mount Sinai Hospital
Chair, Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA)
Former chair, Clinical Research Alliance of the Crohn’s Foundation of America
AGA Fellow (AGAF)
Fellow of the American College of Gastroenterology (FACG)

Mille Long, MD (co-Chair)
Associate Professor of Medicine at University of North Carolina

David Rubin, MD (co-Chair)
Joseph B. Kirsner Professor of Medicine at University of Chicago
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
Member, AGA, ACG, American Society of Gastroenterology Endoscopy, American College of Physicians, and Crohn’s and Colitis Foundation of America

Marla Dubinsky, MD
Professor of Medicine at Mount Sinai Hospital (Pediatrics Lead)

John Hanson, MD
Carolinas Medical Center, Charlotte, NC

Miguel Regueiro, MD
Professor and Chair, Gastroenterology and Hepatology at Cleveland Clinic, Cleveland, OH